Slingshot members are tracking this event:

Bayer's (BAYRY) Stivarga (Regorafenib) Approved for Expanded Indication in Treatment of Patients with Liver Cancer Who Have Been Previously Treated with Sorafenib (Nexavar)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 27, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Stivarga, Regorafenib, Expanded Indication, Liver Cancer, Sorafenib, Nexavar